BCRX Biocryst Pharmaceuticals Inc

Price (delayed)

$7.61

Market cap

$1.96B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.35

Enterprise value

$2.69B

?
Relative Growth: Rel. Growth: 50
Relative Strength: Rel. Strength: 41
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 19

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in ...

Highlights
Biocryst Pharmaceuticals's gross profit has soared by 61% YoY and by 2.3% from the previous quarter
BCRX's revenue has soared by 60% YoY and by 2.2% QoQ
BCRX's equity is up by 13% since the previous quarter but it is down by 2.4% year-on-year
BCRX's debt is up by 21% YoY

Key stats

What are the main financial stats of BCRX

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
-0.91%
1 week
-1.04%
1 month
-5.7%
1 year
10.29%
YTD
-2.44%
QTD
-8.64%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$961.51M
Gross profit
$941.2M
Operating income
-$289.42M
Net income
-$359.66M
Gross margin
97.9%
Net margin
-37.4%
Biocryst Pharmaceuticals's gross profit has soared by 61% YoY and by 2.3% from the previous quarter
BCRX's revenue has soared by 60% YoY and by 2.2% QoQ
The operating margin has grown by 10% from the previous quarter
BCRX's net margin is up by 9% QoQ

Price vs fundamentals

How does BCRX's price correlate with its fundamentals

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.8
BCRX's EPS is up by 6% from the previous quarter
BCRX's equity is up by 13% since the previous quarter but it is down by 2.4% year-on-year
The P/S is 63% lower than the 5-year quarterly average of 5.4 and 12% lower than the last 4 quarters average of 2.3
BCRX's revenue has soared by 60% YoY and by 2.2% QoQ

Efficiency

How efficient is Biocryst Pharmaceuticals business performance
The ROIC rose by 16% QoQ
The company's return on assets rose by 13% QoQ
BCRX's ROS is up by 11% from the previous quarter

Dividends

What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 40% lower than its total liabilities
Biocryst Pharmaceuticals's quick ratio has surged by 59% YoY and by 14% QoQ
Biocryst Pharmaceuticals's current ratio has increased by 45% YoY and by 17% from the previous quarter
BCRX's debt is up by 21% YoY
BCRX's debt to equity is down by 18% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.